Novo Nordisk said on Thursday it filed a marketing application to the U.S. Food and Drug Administration for CagriSema, its once-weekly next-generation weight-loss drug.

Eli Lilly's oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...

A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...

Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week and targeting a booming ...

Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a higher dose of its ...

Indian health-tech startup Healthify is in talks to partner with more weight-loss drugmakers to offer health, nutrition and ...

Denmark on Thursday sharply raised its economic growth forecast for 2025, due in part to the pharmaceuticals industry, which ...

Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...

Novo Nordisk launched Ozempic in India on Friday—and the weight-loss drug will sell at a massive discount there, compared ...

Women with polycystic ovary syndrome are increasingly turning to blockbuster weight-loss drugs from Eli Lilly and Novo ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Dec 2 (Reuters) - Wegovy maker Novo Nordisk (NOVOb.CO), opens new tab is planning to test its experimental obesity drug, CagriSema, in overweight children and adolescents, according to a U.S. registry ...